Back to Journals » OncoTargets and Therapy » Volume 6
Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma
Authors Yuan Z, Tian L, Wang P, Song Y, Dong Y, Zhuang H, Wang J
Received 12 July 2013
Accepted for publication 20 August 2013
Published 29 October 2013 Volume 2013:6 Pages 1527—1532
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Zhiyong Yuan,* Lijun Tian,* Ping Wang, Yongchun Song, Yang Dong, Hongqing Zhuang
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Objective: To retrospectively analyze and compare the outcomes of patients with hepatocellular carcinoma treated with either surgical excision or CyberKnife® from September 2006 to August 2011.
Materials and methods: Local control and toxicity were the primary endpoints, followed by local progression-free survival, progression-free survival, and overall survival as the secondary endpoints. Response Evaluation Criteria In Solid Tumors were the evaluation criteria for efficacy; Common Toxicity Criteria 3.0 were the evaluation criteria for adverse events. Local control was calculated using the direct method (nonactuarial). The survival curves were drawn using the Kaplan–Meier method along with log-rank test analysis.
Results: The research included 26 patients treated with tumor-free cutting edge (R0) surgical excision and 22 patients treated with CyberKnife treatment. The results showed that the adverse effects of CyberKnife were milder, with 1-, 2-, and 3-year local control rates of 92.9%, 90.0%, and 67.7%, respectively. The overall survival rates of the surgical treatment were 88.5%, 73.1%, and 69.2% for the same periods, while those of CyberKnife treatment were 72.7%, 66.7%, and 57.1%, respectively. In this study, surgical excision appeared to prolong overall survival to a greater extent, but with no statistical significance; no statistical difference was observed in the tumor-specific overall survival and progression-free survival between the two cohorts.
Conclusion: According to this preliminary study, with its mild toxicity, the efficacy of CyberKnife treatment for early hepatocellular carcinoma was on par with that of surgical resection.
Keywords: hepatic carcinoma, stereotactic body radiation therapy, hepatectomy
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.